Stock PMVP PMV PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages PMV Pharmaceuticals, Inc.

Equities

PMVP

US69353Y1038

Market Closed - Nasdaq
Other stock markets
 21:00:00 30/04/2024 BST 		5-day change 1st Jan Change
1.8 USD +1.69% Intraday chart for PMV Pharmaceuticals, Inc. -0.28% -41.94%
04-12 Jefferies Starts PMV Pharmaceuticals With Buy Rating, $5 Price Target MT
03-27 PMV Pharmaceuticals, Inc. Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220c-Positive Solid Tumors CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
PMV Pharmaceuticals, Inc. Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220c-Positive Solid Tumors
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
PMV Pharmaceuticals, Inc. Announces Workforce Reduction of Approximately 30%
MORNING BRIEFING - USA/Asien
PMV Pharmaceuticals, Inc. Announces Executive Changes
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
PMV Pharmaceuticals Says Updated Trial Data Show Cancer Therapy Induces Anti-Tumor Activity; Shares Fall
PMV Pharmaceuticals, Inc. Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types with TP53 Y220C Mutation
PMV Pharmaceuticals, Inc. to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
PMV Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
PMV Pharmaceuticals Proposes $200 Million Mixed Shelf Offering
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
PMV Pharmaceuticals, Inc. Announces Board Changes
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
PMV Pharmaceuticals to Collaborate with Merck in Clinical Trial
PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
PMV Pharmaceuticals Shares Fall After Early Trial Data on PC14586
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PMVP Stock
  4. News PMV Pharmaceuticals, Inc.
  5. Other languages